secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-108806
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q3 LINZESS sales up 40% YoY to $315M; raises full-year guidance
------------------------------------------------------------------------

- Q3 GAAP net income $40M ($0.23 diluted EPS) vs $3.6M a year ago; adjusted EBITDA $82M vs $34.5M.
- LINZESS US net sales $315M (+40% YoY); EUTRx demand growth +12% YoY.
- Raises FY2025 LINZESS net sales guidance to $860-$890M; total revenue $290-$310M; adjusted EBITDA >$135M.
- FDA approved LINZESS for IBS-C in children ages 7+; first drug for that indication.
- Plans to align with FDA on apraglutide Phase 3 trial design, start confirmatory study H1 2026; strategic alternatives review ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925108806/0001104659-25-108806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925108806/tm2530577d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-108806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer